



This document may contain statements relating to future results or events, which are forward-looking statements. Words such as “expects”, “intends”, “plans”, “may”, “could”, “should”, “anticipates”, “likely”, “believes” and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company’s business and financial and other results, are contained in the Company’s filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

OTCQB: GBLX
www.gbsciences.com





Cannabis Investment Quiz

What do you call a company that...

- A) Quietly builds an innovative and responsible cannabis company for the long game?
- B) Trades at $\frac{1}{4}$ the value of similar sized companies based purely on cannabis revenue?
- C) Has patented and patentable IP in both Life Sciences and Genetics that is not yet reflected in their valuation or share price?

You call it the elephant in the middle of the room.

GBS truly is the elephant in the middle of the room and we're tickled pink when someone notices.

How to Spot an Elephant in the Middle of the Room

GBLX Comparable Company Valuations

Publicly traded cultivators with similar revenues (in \$US millions)

Cultivator	Market Cap 2/7/18	Quarterly Revenue Annualized	Price / Sales Multiple
Maricann Group	\$267	\$2.5	106
THC Biomed	\$180	\$3.2	56
The Hydrothecary Corp	\$554	\$4.4	126
Supreme Cannabis	\$420	\$6.2	67
OrganiGram Holdings	\$427	\$8.5	50
Average	\$370	\$5.0	81
GB Sciences	\$109	\$5.1	21



(possible elephant)

Elephant Spotting Tips

- Look for the value players that the market hasn't yet realized have hidden assets.
- Stick with them. They're the ones that'll still be standing when the market matures.
- Elephants have a strong, sturdy back and a very long life.
- Enjoy the ride.

(other possible elephant)

A black and white photograph of an elephant's head and trunk, serving as the background for the slide.

An Elephant Once Spotted Is Nearly Impossible To Overlook

But now that you've spotted the elephant, let's get a little closer in.

GBS is a
diverse,
science-based
cannabis company
with three business
focuses

**Cannabis
Products**

Cash flow from cultivation and extraction

**Life
Sciences**

Patented and patentable IP for cannabis-based
medical formulations

**Cannabis
Genetics**

Bringing certified cannabis genetics and GMO's into
the age of modern agriculture

Cannabis Products: Solving the Jumbo Sized Riddles

The jumbo sized riddle has been the inability to produce consistent raw materials for plant based medical formulations.

Until now.



Two things control producing consistent plants – the genetics and the growing environment.



Tissue culture propagation solves the genetic part of the riddle.

- Unlike seeds and clones, tissue propagation produces an exact genetic duplicate of the mother plant.
- We've now taken the variability out of the genetics at the source.



Rigidly controlled growing conditions provide the rest of the answer.

- Every plant is exposed to the same environmental conditions every grow cycle.
- Produces the same plant over and over again.



The Holy Grail of cannabis cultivation!



Elephantidae Hipstericus



Cannabis Products: Our Facility in Las Vegas

The trunk that feeds the beast with recurring monthly revenue. And that's not peanuts.

Precision controlled growing environments enable us to produce a plant that is consistent and beneficial on two levels.

Level 1: Biopharma; we can now grow plants that consistently produce the raw materials in the same quantity and predictable quality necessary to make medicine.

Level 2: We grow beautiful weed.

- It is high in cannabinoids, and terpenes.
- It tastes and smells the same every time with the same psychoactive ingredients so it becomes a very attractive consumer product.
- Repeatable consumer experience.
- This is a powerful competitive advantage.

Cannabis Products: Extraction & Production

The tried and true routines sell tickets and keep 'em coming back for more.

High volume ethanol extraction targeting up to 500,000 grams per month

CO2 extraction for medical formulations

Use oil extracted for medical formulations, edibles, vapes etc.

Tried and true methods just keep producing predictable free cash flow

This is a classic case of "If it ain't broke, don't fix it."



Cannabis Products: Keeping It In the Family

Our Brands :



Creating and Licensing Brands: The best way to build a big, beautiful, extended family.

for medical products

premium flower cannabis recreational products

a complete line of theme based recreational products

CURA
CANNABIS SOLUTIONS

Kush
CUPS




Additional partner discussions
always in progress

Partners
operating under
GB licenses with
royalty or revenue
sharing
agreements



Cannabis Products: Expanding Our Range

Size, strength and adaptability allow our extended family of best in class partners to easily move into new markets. Why try to clone a single elephant when you can just bring the entire herd?





Life Sciences: Our Ivory Tusks

Patents covering multiple conditions

**Cardiovascular Disease: 2016 healthcare burden
over \$500 Billion**

Hypertension, Cardiac Hypertrophy

Neurodegenerative Disorders: Over \$500 Billion

Parkinson's Disease, Alzheimer's Disease, Dementia,
Huntington's Disease

Pain: Over \$600 Billion

Chronic Pain, Immunological Pain, Neuropathic Pain

Inflammatory Disorders: Over \$40 Billion

Eczema, Psoriasis & Dermatitis, Rheumatoid Arthritis & Osteoarthritis,
Inflammatory Bowel Disorder, Crohn's Disease, Asthma



We are much bigger than the box, so it's easy for us to think outside it. Now that's organic value creation.

Accelerated Monetization of Research Through Innovative Thought And Action

Novel FDA Strategy-quicker to First-in-Man

- Using an Exploratory IND & Phase 0 Human Trial
- Multiple formulations taken into Human Trials
- Early indication of efficacy (Phase 0 rather than Phase 2)
- Decreased translational risk (less animal data, more human data)
- Accelerates the monetization of research by years

Phase 0 Trial for Parkinson's Disease imminent

- Toxicity studies summer 2018
- Clinical Trial Guidance by Dr. Zoltan Mari, Section Head of the Nevada Movement Disorders Program and Lee Pascal Parkinson's Disease Scholar at Cleveland Clinic's Lou Ruvo Center for Brain Health and Clinical Professor of Neurology at the University of Nevada, Las Vegas



**Life Sciences:
Thinking Outside**

The Box

Life Sciences: Trustworthy Partners

"An elephant faithful one-hundred percent!"

- Innovative, well-informed, dedicated to real collaboration and cooperation
- Our approach to science has earned us some seriously scientific partners, researchers and advisors from:

- The LSU Agricultural Center
- UNLV
- University of Seville
- Chaminade University
- McLaren Health
- University of Hawaii
- University of Cadiz



Genetics: Herd Mentality

Cooperation is for winners. We like working together for the good of the herd.

The Louisiana State University Agricultural Center is an industry leader in developing proprietary genetics for the agricultural industry. Together, our team of partners can work towards meeting the medical needs of patients. Through scientific based research and technology development, our goal is to:

- Refine process for tissue culture propagation of cannabis
- Develop improved genetics for the cannabis industry
- Utilize the newest technologies to identify output traits



Elephant Think: Our Corporate Culture

Every single team member from the front desk to the C-Suite is smart, committed, and wholly dedicated to maintaining what we like to call 'the vibe'.

This is our corporate culture.

Something that we never forget.


We consider all consumers to be patients.

Everything our team does is grounded in science and innovation.

We embrace close working relationships with multiple research universities and Clinical Research Organizations.

We conduct evidence-based, ground breaking research & development and own multiple patents.

We are the tip of the spear, the industry leader nobody knows about (yet).



Seasoned Management Team



John Poss
Chairman and CEO

With over 30 years of experience, CEO&Chairman John Poss is still thinking outside of the box. He brings expertise in working as a consultant to companies facing major transformations and transitions, and as an executive piloting large and successful companies.



Dr. Andrea Small-Howard
Chief Science Officer

With over 15 years of experience and a PhD from USC, Chief Science Officer, Dr. Small-Howard brings a passion for advancing clinical research on medicinal applications of cannabinoid compounds, strategic vision for creating a vertically-integrated biopharmaceutical pipeline and a track record of successes in the management of biopharmaceutical companies.



Kevin Kuethe
Chief Operating Officer

COO Kevin Kuethe is an innovator with over a decade of industry experience. He is experienced in all aspects of the cannabis industry, including its complex regulatory environment. Kevin oversees all operations pertaining to cultivation, production and facility management that help to ensure quality, quantity and consistency.



Ksenia Griswold
Chief Financial Officer

As VP & CFO, Ksenia Griswold CPA brings to GB an expertise at navigating the best practices and CRISP reporting that are essential for a public company in our highly regulated business. She came to GB from Ernst& Young, LLP.



Tom Arcuragi
Senior VP of Marketing

Senior VP of Marketing Tom Arcuragi is an experienced and innovative programming executive, bringing to GB global sales and marketing expertise. Tom has worked inside a number of industry powerhouses as a loan out executive and as a branding and content consultant for multiple TV networks. Innovating in new markets is his hot button, and GB is about as hot as they come.



TICKER: GBLYOTCQB

PRICE: 02/07/18 \$0.70

52 WEEK RANGE: \$0.21 to \$1.56

MARKET CAP: \$109 MILLION

AVERAGE VOLUME:
3.2 MILLION SHARES

SHARES OUTSTANDING:
156 MILLION



ON SEC FILINGS

GO TO www.gblyotcqb.com
COME ALONG FOR THE RIDE